| Year | Detail |
|---|
| 1946 |
The Stolberg-based entrepreneurial family Wirtz founded a pharmaceutical company named “Chemie Grünenthal GmbH.” |
| 1947 |
Grunenthal acquired a large site in Aachen-Eilendorf from the local government to build a modern research center and raw material production facility. |
| 2020 |
Grunenthal established its Innovation Hub in Boston, Massachusetts, to strengthen and expand its network with leading scientists and institutions. |
| 2020 |
The company acquired the European rights to CRESTOR and its associated brands from AstraZeneca for a total consideration of up to $350 million. |
| 2021 |
The company acquired Mestex AG, a Swiss biotech company that developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with knee osteoarthritis. |
| 2022 |
The company acquired Nebido, the well-known brand for treating male hypogonadism and its associated brands, from Bayer AG. |
| 2022 |
Kyowa Kirin Co., Ltd., a Japan-based global specialty pharmaceutical company, signed a joint venture with Grunenthal to develop Kyowa Kirin International's established medicines portfolio. |
| 2023 |
Grunenthal and King’s College London collaborated to develop microfluidic culture (MFC) models based on human induced pluripotent stem cells (iPSCs) tailored to pain research. |
| 2024 |
The company acquired US-based Valinor Pharma, LLC. and its product Movantik, with a total deal value of approximately $250 million, including all royalty obligations. This acquisition will further expand Grunenthal's portfolio of established medicines and add to the company’s growing U.S. business. |
